Dasatinib may be effective against several cancers
the ONA take:
According to a new study published in the journal Molecular Carcinogenesis, dasatinib (Sprycel) may be effective for the treatment of breast, skin, and various other cancers. Researchers found that dasatinib, a tyrosine kinase inhibitor that targets the Bcr-Abl oncogene, was effective in vitro at inhibiting Fyn, a protein similar to Bcr-Abl.
Fyn is known for being involved cell-cell adhesion and cell migration and is found in brain, breast, head-and-neck, pancreatic, and skin cancers.
Mitchell Dennings, PhD, and his colleagues applied dasatinib to cancer cells in vitro and observed the cells clumping together as well a halt in cell migration. The team found similar results when using breast cancer cells. When administered to mice with skin cancer, dasatinib decreased the quantity and size of their tumors.
Clinical trials are currently underway to study dasatinib's effects in patients with acute lymphoblastic lymphoma, endometrial cancer, gastrointestinal stromal cancer, Hodgkin's lymphoma, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, and prostate cancer.
Dasatinib was initially approved by the U.S. Food and Drug Administration in 2006 and is indicated for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. It is administered orally once daily.
Dasatinib shows promise for treating skin, breast and several other cancers.
Dasatinib fights leukemia by checking the uncontrolled growth of cancer cells. But when used against other cancer cells, researchers found, the drug employs a different strategy: It causes the cells to clump together, thus preventing them from migrating. Without the ability to migrate, cancer cells cannot metastasize (spread to other parts of the body).
Mitchell Denning, PhD, and colleagues discovered the molecular mechanism behind this cell-cell adhesion. The researchers reported their findings in a study published online ahead of print in the journal Molecular Carcinogenesis.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer
- Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women
- Live-streamed Videos Address End-of-Life Planning, Decision-making
- Metastatic Disease Linked to Patients Reporting Diminished QoL
- History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis
- Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|